Key result
Thyroxin replacement therapy to achieve a euthyroid state decreased daytime systolic blood pressure by 8.5 mm Hg (95% CI 5.5-11.5) in patients with primary hypothyroidism and hypertension.
Why the study?
Does thyroxin replacement therapy reduce blood pressure and interstitial fluid volume in patients with primary hypothyroidism and arterial hypertension?
Observational (n=49)
Does thyroxin replacement therapy reduce blood pressure and interstitial fluid volume in patients with primary hypothyroidism and arterial hypertension?
Mean Difference: 8.5 (95% CI 5.5–11.5)
Thyroxin replacement therapy significantly reduces blood pressure, left ventricular mass index, and interstitial fluid volume in patients with primary hypothyroidism and arterial hypertension.
Thyroxine replacement may lower daytime SBP in hypothyroid hypertension; leaves open need for RCTs before practice change.
Objective. To investigate short-term effects of thyroxin replacement therapy on blood pressure (BP), left ventricular mass index (LVMI), interstitial fluid volume (IFV) and skin vessels resistance in patients with first diagnosed primary hypothyroidism (PH) and past history of arterial hypertension (AH). Design and methods. 49 patients with PH and AH were examined twice: before the therapy onset and after euthyroid state was achieved. All patients underwent daily BP monitoring, echocardiography, body integral rheography and high frequency ultrasound dopplerography of nail ridge arterioles. Results. Decrease in daytime systolic BP by 8.5 (95 % CI: 5.5-11.5) mm Hg, nighttime systolic BP by 5.3 (2.5-8.1) mm Hg, daytime diastolic BP by 3.8 (1.2-6.4) mm Hg, nighttime diastolic BP by 3.5 (0.9-6.1) mm Hg, IFV by 1.5 (0.11-2.91) l, LVMI by 8.5 (1.9-15.0) g/m 2 and Purselo index by 0.19 (0.05-0.33) units (or 25 % to initial level) were found in patients with PH when euthyroid state was achieved. Conclusion. IFV can play a key role in AH development in patients with PH.
No takes yet. Share an insight, caveat, or question.
Мазур et al. (2012) conducted an observational in Primary hypothyroidism and arterial hypertension (n=49). Thyroxin replacement therapy vs. Baseline (before therapy onset) was evaluated on Daytime systolic blood pressure (Decrease of 8.5 mm Hg, 95% CI 5.5-11.5). Thyroxin replacement therapy to achieve a euthyroid state decreased daytime systolic blood pressure by 8.5 mm Hg (95% CI 5.5-11.5) in patients with primary hypothyroidism and hypertension.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: